LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

Strona główna・Stock List・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Open

SectorHealthcare

31.18 3.11

Buy Sell

Overview

Share price change

24h

Current

Min

30.05

Max

31.11

Key metrics
By Trading Economics
Income	10M 32M
Sales	-28M 215M
P/E Sector Avg	12.169 51.415
EPS	0.786
Profit margin	15.084
Employees	293
EBITDA	-2.8M 49M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+44.08% upside

Dividends
By Dow Jones
Next Earnings	4 sie 2026

Market Stats
By TradingEconomics
Market Cap	-139M 1.7B
Previous open	28.07
Previous close	31.18

News Sentiment

By Acuity

40%

60%

127 / 346 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

29.8 / N/A Support & Resistance

Harmony Biosciences Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 maj 2026, 22:54 UTC

Earnings

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 maj 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 maj 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 maj 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 maj 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13 maj 2026, 23:17 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 maj 2026, 23:16 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 maj 2026, 23:15 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 maj 2026, 23:14 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 maj 2026, 23:02 UTC

Market Talk

Earnings

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 maj 2026, 22:59 UTC

Market Talk

Earnings

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 maj 2026, 22:24 UTC

Earnings

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 maj 2026, 22:23 UTC

Earnings

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 maj 2026, 22:23 UTC

Earnings

Xero FY International Revenue Growth 47%>XRO.AU

13 maj 2026, 22:22 UTC

Earnings

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 maj 2026, 22:19 UTC

Earnings

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 maj 2026, 22:19 UTC

Earnings

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 maj 2026, 22:18 UTC

Earnings

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 maj 2026, 22:16 UTC

Earnings

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 maj 2026, 22:15 UTC

Earnings

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 maj 2026, 22:15 UTC

Earnings

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 maj 2026, 22:13 UTC

Earnings

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 maj 2026, 22:12 UTC

Earnings

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 maj 2026, 22:11 UTC

Earnings

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 maj 2026, 22:11 UTC

Earnings

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 maj 2026, 22:10 UTC

Earnings

Xero Did Not Declare a Dividend>XRO.AU

13 maj 2026, 22:10 UTC

Earnings

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 maj 2026, 22:09 UTC

Earnings

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 maj 2026, 22:00 UTC

Earnings

Cisco to Shed Jobs for All-In AI Push -- Update

13 maj 2026, 21:11 UTC

Earnings

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Peer Comparison

Price change

Harmony Biosciences Holdings Inc Forecast

Price Target

By TipRanks

44.08% upside

12 Months Forecast

Average 43.44 USD 44.08%

High 72 USD

Low 28 USD

Based on 9 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Harmony Biosciences Holdings Inc - Dist in the past 3 months.

Technical Score

By Trading Central

29.8 / N/ASupport & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

127 / 346 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.